In the first half of 2026, the boom in the AI pharmaceutical industry increased significantly, and the commercialization process accelerated markedly. The overall performance of the Hong Kong stock AI Pharmaceuticals “Three Little Dragons” improved in the first half of the year: Insilicon Smart turned a loss into a profit; Jietai Technology's revenue increased sharply and adjusted net loss narrowed significantly; and Jingtai Technology's AI4S business grew sharply. Also, according to Choice data, as of August 30, of the 73 A-share AI pharmaceutical concept stocks that have announced semi-annual results, the net profit of more than 50% of the companies achieved year-on-year growth, and the AI pharmaceutical industry has accelerated its shift from technological exploration to commercial value realization. Judging from the semi-annual report, the boom in the AI pharmaceutical industry has increased significantly. Among them, high-value BD has now become an important driving force for the performance growth of listed companies.

In the first half of 2026, the boom in the AI pharmaceutical industry increased significantly, and the commercialization process accelerated markedly. The overall performance of the Hong Kong stock AI Pharmaceuticals “Three Little Dragons” improved in the first half of the year: Insilicon Smart turned a loss into a profit; Jietai Technology's revenue increased sharply and adjusted net loss narrowed significantly; and Jingtai Technology's AI4S business grew sharply. Also, according to Choice data, as of August 30, of the 73 A-share AI pharmaceutical concept stocks that have announced semi-annual results, the net profit of more than 50% of the companies achieved year-on-year growth, and the AI pharmaceutical industry has accelerated its shift from technological exploration to commercial value realization. Judging from the semi-annual report, the boom in the AI pharmaceutical industry has increased significantly. Among them, high-value BD has now become an important driving force for the performance growth of listed companies.